Analysis Tools
neoplasm
|
• mice develop solid tumors starting at 8 months of age at various locations of the body, including diaphragm, limb, spine, retroperitoneum, and subcutaneous regions
• by 13 months of age, all mice develop tumors
• tumors are identified as dedifferentiated liposarcomas
• treatment with rosigliatazone starting at 7 months of age prevents liposarcoma formation at 15 months of age
|
adipose tissue
|
• epididymal white adipose tissue is not visible in mice older than 5 months of age
|
|
• adipose tissues of adults, but not 3 week old mice, express lower levels of mature adipocyte markers, indicating dedifferentiation of white adipocytes
• mice treated with rosiglitazone, show reactivation of mature adipocyte marker expression
|
|
• adults gradually develop lipodystrophy, resulting in an approximate 90% reduction of adipose tissue weights
• mice treated with rosiglitazone, a synthetic Ppar-gamma ligand and antidiabetic drug, show increased size and weight of adipose tissues
|
cellular
|
• adipose tissues of adults, but not 3 week old mice, express lower levels of mature adipocyte markers, indicating dedifferentiation of white adipocytes
• mice treated with rosiglitazone, show reactivation of mature adipocyte marker expression
|
growth/size/body
|
• mice are resistant to high-fat diet-induced body weight gain
|
homeostasis/metabolism
|
• mice are resistant to high-fat diet-induced body weight gain
|
|
• 15-fold and 40-fold increase in circulating insulin levels under fasted and re-fed conditions, respectively
• treatment with rosigliatazone rescues the diabetes
|
|
• 15-fold and 40-fold increase in circulating insulin levels under fasted and re-fed conditions, respectively, indicating severe insulin resistance
• mice fail to respond to insulin in all time points during the 2-hour insulin tolerance tests on both a chow diet and high-fat diet
|
liver/biliary system
|
• livers show very high fat content accompanied by elevated expression levels of genes involved in lipid metabolism
|
